<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36454631</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Chronic viral coinfections differentially affect the likelihood of developing long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e163669</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI163669</ELocationID><Abstract><AbstractText>BACKGROUNDThe presence and reactivation of chronic viral infections, such as EBV, CMV, and HIV, have been proposed as potential contributors to long COVID (LC), but studies in well-characterized postacute cohorts of individuals with COVID-19 over a longer time course consistent with current case definitions of LC are limited.METHODSIn a cohort of 280 adults with prior SARS-CoV-2 infection, we assessed the presence and types of LC symptoms and prior medical history (including COVID-19 history and HIV status) and performed serological testing for EBV and CMV using a commercial laboratory. We used covariate-adjusted binary logistic regression models to identify independent associations between variables and LC symptoms.RESULTSWe observed that LC symptoms, such as fatigue and neurocognitive dysfunction, at a median of 4 months following initial diagnosis were independently associated with serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) or high nuclear antigen (EBNA) IgG levels but not with ongoing EBV viremia. Serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity) was most strongly associated with fatigue (OR = 2.12). Underlying HIV infection was also independently associated with neurocognitive LC (OR = 2.5). Interestingly, participants who had serologic evidence of prior CMV infection were less likely to develop neurocognitive LC (OR = 0.52).CONCLUSIONOverall, these findings suggest differential effects of chronic viral coinfections on the likelihood of developing LC and association with distinct syndromic patterns. Further assessment during the acute phase of COVID-19 is warranted.TRIAL REGISTRATIONLong-term Impact of Infection with Novel Coronavirus; ClinicalTrials.gov NCT04362150.FUNDINGThis work was supported by NIH/National Institute of Allergy and Infectious Diseases grants (3R01AI141003-03S1, R01AI158013, and K24AI145806); the Zuckerberg San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine; and the UCSF-Bay Area Center for AIDS Research (P30-AI027763).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryder</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck-Engeser</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Fay</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Leonel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Nikita S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deswal</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Lynn H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buitrago</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jessica Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Brandon C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenna</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winslow</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>Christos J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Amelia N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>School of Pharmacy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellmuth</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04362150</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI145806</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167648</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG075262</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI027763</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL152957</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2022 Jul 22:2022.06.21.22276660. doi: 10.1101/2022.06.21.22276660</RefSource><PMID Version="1">35898346</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003586" MajorTopicYN="Y">Cytomegalovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive immunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>12</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36454631</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pii">163669</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation> WHO. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6 October 2021.  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 Updated October 6, 2021. Accessed November 30, 2022.</Citation></Reference><Reference><Citation>Peluso MJ, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome Coronavirus 2 infection. J Infect Dis. 2021;224(11):1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;1(2):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, et al. The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci. 2021;1(11):1522&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="pubmed">34675436</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;0(5):881&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, et al. Persistent symptoms in adult patients 1 year after Coronavirus Disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2013;1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D, et al. SARS-CoV-2 infection and persistence throughout the human body and brain [preprint]. Posted on Research Square on December 20, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (NY) 2022;3(6):371&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, et al. Post-acute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163(2):495&#x2013;506. doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, et al. A longitudinal Study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022;175(7):969&#x2013;979. doi: 10.7326/M21-4905.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4905</ArticleId><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Lack of antinuclear antibodies in convalescent COVID-19 patients with persistent symptoms. Clin Infect Dis. 2022;74(11):2083&#x2013;2084. doi: 10.1093/cid/ciab890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab890</ArticleId><ArticleId IdType="pmc">PMC9187313</ArticleId><ArticleId IdType="pubmed">34617982</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268&#x2013;270. doi: 10.1016/j.it.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunmire SK, et al. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84&#x2013;92. doi: 10.1016/j.jcv.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2018.03.001</ArticleId><ArticleId IdType="pubmed">29525635</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp JM. Epstein-Barr Virus-specific humoral immune responses in health and disease. Curr Top Microbiol Immunol. 2015;391:289&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">26428379</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, et al. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Oral Oncol. 2019;93:85&#x2013;90. doi: 10.1016/j.oraloncology.2019.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2019.04.024</ArticleId><ArticleId IdType="pubmed">31109701</ArticleId></ArticleIdList></Reference><Reference><Citation>Fechtner S, et al. Antibody responses to Epstein-Barr Virus in the preclinical period of rheumatoid arthritis suggest the presence of increased viral reactivation cycles. Arthritis Rheumatol. 2022;74(4):597&#x2013;603. doi: 10.1002/art.41994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41994</ArticleId><ArticleId IdType="pmc">PMC8957485</ArticleId><ArticleId IdType="pubmed">34605217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296&#x2013;301. doi: 10.1126/science.abj8222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloisi F, Salvetti M. Epstein-Barr virus and multiple sclerosis: supporting causality. Lancet Neurol. 2022;21(4):300&#x2013;301. doi: 10.1016/S1474-4422(22)00086-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00086-2</ArticleId><ArticleId IdType="pubmed">35305331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, et al. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11(1):10902. doi: 10.1038/s41598-021-90351-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90351-y</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021;104:315&#x2013;319. doi: 10.1016/j.ijid.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51(3):296&#x2013;299. doi: 10.1016/j.idnow.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner GF, et al. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit Care. 2020;24(1):657. doi: 10.1186/s13054-020-03384-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03384-6</ArticleId><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, et al. SARS-CoV-2 respiratory co-infections: Incidence of viral and bacterial co-pathogens. Int J Infect Dis. 2021;105:617&#x2013;620. doi: 10.1016/j.ijid.2021.02.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.087</ArticleId><ArticleId IdType="pmc">PMC7905386</ArticleId><ArticleId IdType="pubmed">33640570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, et al. Investigation of long COVID prevalence and its relationship to Epstein-Barr Virus reactivation. Pathogens. 2021;10(6):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Klutts JS, et al. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol. 2009;47(10):3204&#x2013;3210. doi: 10.1128/JCM.00164-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00164-09</ArticleId><ArticleId IdType="pmc">PMC2756947</ArticleId><ArticleId IdType="pubmed">19656988</ArticleId></ArticleIdList></Reference><Reference><Citation> US CDC. Epstein-Barr Virus Laboratory Testing.  https://www.cdc.gov/epstein-barr/laboratory-testing.html Updated September 28, 2022. Accessed November 30, 2022.</Citation></Reference><Reference><Citation>Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004;42(8):3381&#x2013;3387. doi: 10.1128/JCM.42.8.3381-3387.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.8.3381-3387.2004</ArticleId><ArticleId IdType="pmc">PMC497621</ArticleId><ArticleId IdType="pubmed">15297472</ArticleId></ArticleIdList></Reference><Reference><Citation>Paramita DK, et al. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol. 2007;79(11):1710&#x2013;1721. doi: 10.1002/jmv.20987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20987</ArticleId><ArticleId IdType="pubmed">17854043</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G, Trier NH. Epstein-Barr Virus and systemic autoimmune diseases. Front Immunol. 2020;11:587380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole BD, et al. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39(1):63&#x2013;70. doi: 10.1080/08916930500484849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930500484849</ArticleId><ArticleId IdType="pubmed">16455583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TV, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321&#x2013;327. doi: 10.1038/s41586-022-04432-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04432-7</ArticleId><ArticleId IdType="pmc">PMC9382663</ArticleId><ArticleId IdType="pubmed">35073561</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber S, et al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PLoS One. 2022;17(5):e0268530. doi: 10.1371/journal.pone.0268530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268530</ArticleId><ArticleId IdType="pmc">PMC9132318</ArticleId><ArticleId IdType="pubmed">35613127</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanio C, et al. Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization. J Infect Dis. 2022;226(3):463&#x2013;473. doi: 10.1093/infdis/jiac020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac020</ArticleId><ArticleId IdType="pmc">PMC8905965</ArticleId><ArticleId IdType="pubmed">35134186</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-CoV-2 infection. AIDS. 2022;36(12):F7&#x2013;F16. doi: 10.1097/QAD.0000000000003338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003338</ArticleId><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingery JR, et al. Health status, persistent symptoms, and effort intolerance one year after acute COVID-19 infection. J Gen Intern Med. 2022;37(5):1218&#x2013;1225. doi: 10.1007/s11606-021-07379-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-07379-z</ArticleId><ArticleId IdType="pmc">PMC8786200</ArticleId><ArticleId IdType="pubmed">35075531</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200003. doi: 10.1212/NXI.0000000000200003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight. 2022;7(10):e157053. doi: 10.1172/jci.insight.157053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157053</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Damania B, et al. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185(20):3652&#x2013;3670. doi: 10.1016/j.cell.2022.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.08.026</ArticleId><ArticleId IdType="pmc">PMC9529843</ArticleId><ArticleId IdType="pubmed">36113467</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole BD, et al. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev. 2009;8(4):337&#x2013;342. doi: 10.1016/j.autrev.2008.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.12.008</ArticleId><ArticleId IdType="pmc">PMC2822456</ArticleId><ArticleId IdType="pubmed">19167523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sep&#xfa;lveda N, et al. Revisiting IgG antibody reactivity to Epstein-Barr virus in myalgic encephalomyelitis/chronic fatigue syndrome and its potential application to disease diagnosis. Front Med (Lausanne) 2022;9:921101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9263839</ArticleId><ArticleId IdType="pubmed">35814774</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437&#x2013;442. doi: 10.1038/s41586-020-2456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Frappier L. The Epstein-Barr Virus EBNA1 protein. Scientifica. 2012;2012:438204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820569</ArticleId><ArticleId IdType="pubmed">24278697</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, et al. Distinguishing features of Long COVID identified through immune profiling [preprint]. Posted on medRxiv August 10, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsten CB, et al. Evolution of functional antibodies following acute Epstein-Barr virus infection. PLoS Pathog. 2022;18(9):e1010738. doi: 10.1371/journal.ppat.1010738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010738</ArticleId><ArticleId IdType="pmc">PMC9481173</ArticleId><ArticleId IdType="pubmed">36067220</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med. 2015;7(281):281ra43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505610</ArticleId><ArticleId IdType="pubmed">25834109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikby A, et al. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37(2-3):445&#x2013;453. doi: 10.1016/S0531-5565(01)00212-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(01)00212-1</ArticleId><ArticleId IdType="pubmed">11772532</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole E, et al. Human cytomegalovirus interleukin 10 homologs: facing the immune system. Front Cell Infect Microbiol. 2020;10:245. doi: 10.3389/fcimb.2020.00245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00245</ArticleId><ArticleId IdType="pmc">PMC7296156</ArticleId><ArticleId IdType="pubmed">32582563</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol. 2022;9(2):221&#x2013;226. doi: 10.1002/acn3.51498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51498</ArticleId><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcendor DJ, et al. Infection and upregulation of proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus. J Neuroinflammation. 2012;9:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413582</ArticleId><ArticleId IdType="pubmed">22607552</ArticleId></ArticleIdList></Reference><Reference><Citation>Shnayder M, et al. Defining the transcriptional landscape during cytomegalovirus latency with single-cell RNA sequencing. mBio. 2018;9(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5850328</ArticleId><ArticleId IdType="pubmed">29535194</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury G, et al. Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy. J Infect Dis. 2017;215(6):911&#x2013;919. doi: 10.1093/infdis/jix039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix039</ArticleId><ArticleId IdType="pmc">PMC5407052</ArticleId><ArticleId IdType="pubmed">28453847</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS. 2022;36(12):F7&#x2013;F16. doi: 10.1097/QAD.0000000000003338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003338</ArticleId><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114(12):865&#x2013;871. doi: 10.1093/qjmed/hcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, et al. Case report of breakthrough long COVID and the use of nirmatrelvir-ritonavir [preprint]. Posted on Research Square on March 15, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1443341/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M, et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7(1):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Persistence, magnitude and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. Open Forum Infect Dis. 2021;9(2):ofab640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation> CDC. Symptoms of COVID-19. Centers for Disease Control and Prevention.  https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html Updated October 26, 2022. Accessed November 30, 2022.</Citation></Reference><Reference><Citation>Kroenke K, et al. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258&#x2013;266. doi: 10.1097/00006842-200203000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-200203000-00008</ArticleId><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;109518(6):109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Staras SAS, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43(9):1143&#x2013;1151. doi: 10.1086/508173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/508173</ArticleId><ArticleId IdType="pubmed">17029132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>